200 related articles for article (PubMed ID: 28363321)
1. Buprenorphine physician supply: Relationship with state-level prescription opioid mortality.
Knudsen HK; Havens JR; Lofwall MR; Studts JL; Walsh SL
Drug Alcohol Depend; 2017 Apr; 173 Suppl 1(Suppl 1):S55-S64. PubMed ID: 28363321
[TBL] [Abstract][Full Text] [Related]
2. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
3. Health Care Utilization of Opioid Overdose Decedents with No Opioid Analgesic Prescription History.
Abbasi AB; Salisbury-Afshar E; Jovanov D; Berberet C; Arunkumar P; Aks SE; Layden JE; Pho MT
J Urban Health; 2019 Feb; 96(1):38-48. PubMed ID: 30607879
[TBL] [Abstract][Full Text] [Related]
4. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.
Knudsen HK; Lofwall MR; Havens JR; Walsh SL
Drug Alcohol Depend; 2015 Dec; 157():36-43. PubMed ID: 26483356
[TBL] [Abstract][Full Text] [Related]
5. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
[TBL] [Abstract][Full Text] [Related]
6. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
[TBL] [Abstract][Full Text] [Related]
8. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
Currie JM; Schnell MK; Schwandt H; Zhang J
JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
[TBL] [Abstract][Full Text] [Related]
9. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic.
Tanz LJ; Jones CM; Davis NL; Compton WM; Baldwin GT; Han B; Volkow ND
JAMA Netw Open; 2023 Jan; 6(1):e2251856. PubMed ID: 36662523
[TBL] [Abstract][Full Text] [Related]
10. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries.
Samples H; Nowels MA; Williams AR; Olfson M; Crystal S
Am J Prev Med; 2023 Jul; 65(1):19-29. PubMed ID: 36906496
[TBL] [Abstract][Full Text] [Related]
12. A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients.
Chang HY; Krawczyk N; Schneider KE; Ferris L; Eisenberg M; Richards TM; Lyons BC; Jackson K; Weiner JP; Saloner B
Drug Alcohol Depend; 2019 Aug; 201():127-133. PubMed ID: 31207453
[TBL] [Abstract][Full Text] [Related]
13. Comparison between buprenorphine provider availability and opioid deaths among US counties.
Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R
J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537
[TBL] [Abstract][Full Text] [Related]
14. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
Krawczyk N; Jent V; Hadland SE; Cerdá M
J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
[TBL] [Abstract][Full Text] [Related]
15. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
[TBL] [Abstract][Full Text] [Related]
16. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
[TBL] [Abstract][Full Text] [Related]
17. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.
Knudsen HK
J Stud Alcohol Drugs; 2015 Jul; 76(4):644-54. PubMed ID: 26098042
[TBL] [Abstract][Full Text] [Related]
18. Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality.
Lei F; Lofwall MR; McAninch J; Adatorwovor R; Slade E; Freeman PR; Moga DC; Dasgupta N; Walsh SL; Vickers-Smith R; Slavova S
J Addict Med; 2024 May-Jun 01; 18(3):319-326. PubMed ID: 38598300
[TBL] [Abstract][Full Text] [Related]
19. The Burden of Opioid-Related Mortality in the United States.
Gomes T; Tadrous M; Mamdani MM; Paterson JM; Juurlink DN
JAMA Netw Open; 2018 Jun; 1(2):e180217. PubMed ID: 30646062
[TBL] [Abstract][Full Text] [Related]
20. Changing Trends in Opioid Overdose Deaths and Prescription Opioid Receipt Among Veterans.
Lin LA; Peltzman T; McCarthy JF; Oliva EM; Trafton JA; Bohnert ASB
Am J Prev Med; 2019 Jul; 57(1):106-110. PubMed ID: 31128955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]